Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome.

Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG

The Journal of clinical endocrinology and metabolism1 Jul 1993Cited by 69 (Europe PMC)

PMID7686916DOI10.1210/jcem.77.1.7686916PepBankPUB-07686916

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study17

16 results from studies that gave the peptide. 16 results from people.

01HumanNon-randomized trialSafety outcome
Adults with GHRD had no hypoglycemia below 2.5 mmol/L during IGF-I treatment.
In plain wordsAdults with GHRD had no blood sugar levels below the stated hypoglycemia threshold during IGF-I treatment.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHypoglycemia
Study
n = 6
Outcome group
Adverse events · Metabolic and weight
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Glucose threshold defining hypoglycemia
< 2.5 mmol/L
During IGF-I treatment, adults with GHRD
Source sentences
Summary
Hypoglycemia (< 2.5 mmol/L) did not occur, and mean 2 h postprandial insulin levels were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691602
02HumanNon-randomized trialEfficacy outcome
IGF-I reduced mean postprandial insulin in adults with GHRD.
In plain wordsIGF-I reduced insulin after meals in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreasePostprandial insulin
Study
n = 6
Outcome group
Glycemic control · Metabolic and weight
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Hypoglycemia (< 2.5 mmol/L) did not occur, and mean 2 h postprandial insulin levels were reduced.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691603
03HumanNon-randomized trialEfficacy outcome
IGF-I increased urinary calcium twofold in adults with GHRD.
In plain wordsIGF-I increased calcium in urine in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseUrinary calcium
Study
n = 6
Outcome group
Kidney function · Kidney and urinary
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Urinary calcium change
2 fold
During IGF-I therapy, adults with GHRD
P value for urinary calcium increase
< 0.01
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
Urinary calcium increased 2-fold (P < 0.01), and serum calcium was unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691604
04HumanNon-randomized trialEfficacy outcome
Serum calcium did not change during IGF-I treatment in adults with GHRD.
In plain wordsBlood calcium did not change during IGF-I treatment in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeSerum calcium
Study
n = 6
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Urinary calcium increased 2-fold (P < 0.01), and serum calcium was unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691605
05HumanNon-randomized trialEfficacy outcome
IGF-I suppressed integrated GH levels in adults with GHRD.
In plain wordsIGF-I reduced growth hormone levels in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIntegrated GH level
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Mean integrated 24-h GH level
6.5 micrograms/L
Before IGF-I, adults with GHRD
Mean integrated 24-h GH level
1 micrograms/L
During IGF-I, adults with GHRD
Reported +/- uncertainty of mean integrated 24-h GH level (type unspecified)
2.1 micrograms/L
Before IGF-I, adults with GHRD
Reported +/- uncertainty of mean integrated 24-h GH level (type unspecified)
0.2 micrograms/L
During IGF-I, adults with GHRD
P value for mean integrated 24-h GH suppression
< 0.05
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 micrograms/L), as were the number of peaks, area under the curve, and clonidine-stimulated GH release (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691606
06HumanNon-randomized trialEfficacy outcome
IGF-I reduced the number of GH peaks in adults with GHRD.
In plain wordsIGF-I reduced growth hormone peaks in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH peaks
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
P value for GH peak number reduction
< 0.05
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 micrograms/L), as were the number of peaks, area under the curve, and clonidine-stimulated GH release (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691607
07HumanNon-randomized trialEfficacy outcome
IGF-I reduced GH area under the curve in adults with GHRD.
In plain wordsIGF-I reduced overall growth hormone exposure in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseGH area under curve
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
P value for GH area under the curve reduction
< 0.05
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 micrograms/L), as were the number of peaks, area under the curve, and clonidine-stimulated GH release (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691608
08HumanNon-randomized trialEfficacy outcome
IGF-I suppressed clonidine-stimulated GH release in adults with GHRD.
In plain wordsIGF-I reduced growth hormone release after clonidine in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseClonidine-stimulated GH release
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
P value for clonidine-stimulated GH release suppression
< 0.05
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
The mean integrated 24-h GH level was suppressed (6.5 +/- 2.1 to 1 +/- 0.2 micrograms/L), as were the number of peaks, area under the curve, and clonidine-stimulated GH release (all P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691609
09HumanNon-randomized trialPharmacokinetics
In adults with GHRD, IGF-I reached a peak between 2-6 h after injection and remained elevated at 12 h.
In plain wordsIn adults with GHRD, IGF-I levels peaked after injection and remained above pretreatment levels.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseIGF-I concentrations
Study
n = 6
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Mean pretreatment IGF-I level
36 micrograms/L
Before IGF-I, adults with GHRD
Pretreatment IGF-I as share of Ecuadorian control value
19%
Before IGF-I, adults with GHRD
Ecuadorian control IGF-I value
190 micrograms/L
Control subjects
Peak IGF-I level
253 micrograms/L
2-6 h after IGF-I injection
IGF-I level at 12 h
137 micrograms/L
12 h after IGF-I injection
Reported +/- uncertainty of mean pretreatment IGF-I level (type unspecified)
2 micrograms/L
Before IGF-I, adults with GHRD
Reported +/- uncertainty of peak IGF-I level (type unspecified)
11 micrograms/L
2-6 h after IGF-I injection
Reported +/- uncertainty of IGF-I level at 12 h (type unspecified)
8 micrograms/L
12 h after IGF-I injection
1 more measurement in the study.
Source sentences
Summary
The mean pretreatment IGF-I level (36 +/- 2 micrograms/L) was 19% of the Ecuadorian control value (190 +/- 15 micrograms/L), it achieved a peak (253 +/- 11 micrograms/L) between 2-6 h after IGF-I injection, and at 12 h it was 137 +/- 8 micrograms/L.
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691610
10HumanNon-randomized trialPharmacokinetics
IGF-I half-life did not significantly differ between days 1 and 7 in adults with GHRD.
In plain wordsIn adults with GHRD, IGF-I half-life did not differ significantly between the first and last treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeHalf-life
Study
n = 6
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Half-life
8.2 h
Day 1
Half-life
9.7 h
Day 7
Reported +/- uncertainty of half-life (type unspecified)
1.5 h
Day 1, adults with GHRD
Reported +/- uncertainty of half-life (type unspecified)
1.9 h
Day 7, adults with GHRD
Source sentences
Summary
There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691611
11HumanNon-randomized trialPharmacokinetics
IGF-I metabolic clearance did not significantly differ between days 1 and 7 in adults with GHRD.
In plain wordsIn adults with GHRD, IGF-I clearance did not differ significantly between the first and last treatment days.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeMetabolic clearance
Study
n = 6
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Metabolic clearance
0.35 mL/kg.min
Day 1
Metabolic clearance
0.24 mL/kg.min
Day 7
Reported +/- uncertainty of metabolic clearance (type unspecified)
0.1 mL/kg.min
Day 1, adults with GHRD
Reported +/- uncertainty of metabolic clearance (type unspecified)
0.05 mL/kg.min
Day 7, adults with GHRD
Source sentences
Summary
There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691612
12HumanNon-randomized trialPharmacokinetics
IGF-I distribution volume increased between days 1 and 7 in adults with GHRD.
In plain wordsIn adults with GHRD, IGF-I distribution volume increased from the first to the last treatment day.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseDistribution volume
Study
n = 6
Comparator
Day 1
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Distribution volume
183 mL/kg
Day 1
Distribution volume
266 mL/kg
Day 7
Reported +/- uncertainty of distribution volume (type unspecified)
10 mL/kg
Day 1, adults with GHRD
Reported +/- uncertainty of distribution volume (type unspecified)
36 mL/kg
Day 7, adults with GHRD
P value for distribution volume increase
< 0.03
Day 7 versus day 1, adults with GHRD
Source sentences
Summary
There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691613
13HumanNon-randomized trialEfficacy outcome
IGF-I reduced IGF-II levels in adults with GHRD.
In plain wordsIGF-I reduced IGF-II levels in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIGF-II levels
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Baseline IGF-II as share of control value
47%
Before IGF-I, adults with GHRD
IGF-II level
273 micrograms/L
Before IGF-I therapy
IGF-II level
178 micrograms/L
During IGF-I therapy
Reported +/- uncertainty of IGF-II level (type unspecified)
10 micrograms/L
Before IGF-I therapy
Reported +/- uncertainty of IGF-II level (type unspecified)
9 micrograms/L
During IGF-I therapy
P value for IGF-II decrease
< 0.01
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
Baseline IGF-II levels were 47% of the control value and decreased during IGF-I therapy (273 +/- 10 to 178 +/- 9 micrograms/L; P < 0.01), correlating inversely with IGF-I levels (r = -0.3; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691614
14HumanNon-randomized trialMechanism
During IGF-I therapy in adults with GHRD, IGF-II levels correlated inversely with measured IGF-I levels.
In plain wordsIn adults with GHRD receiving IGF-I, higher measured IGF-I levels were linked to lower IGF-II levels.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseIGF-I and IGF-II correlation
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Correlation of IGF-II with IGF-I levels (r)
−0.3
During IGF-I therapy, adults with GHRD
P value for inverse correlation of IGF-II with IGF-I levels
< 0.001
During IGF-I therapy, adults with GHRD
Source sentences
Summary
Baseline IGF-II levels were 47% of the control value and decreased during IGF-I therapy (273 +/- 10 to 178 +/- 9 micrograms/L; P < 0.01), correlating inversely with IGF-I levels (r = -0.3; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691615
15HumanNon-randomized trialEfficacy outcome
IGF-I did not significantly affect IGFBP-3 levels in adults with GHRD.
In plain wordsIGF-I did not significantly change IGFBP-3 levels in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIGFBP-3 levels
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Although IGF-binding protein-3 (IGFBP-3) levels were not significantly influenced, baseline IGFBP-2 levels (153% of the control) increased 45% (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691616
16HumanNon-randomized trialEfficacy outcome
IGF-I increased IGFBP-2 levels in adults with GHRD.
In plain wordsIGF-I increased IGFBP-2 levels in adults with GHRD.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseIGFBP-2 levels
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
40 micrograms/kg every 12 h · subcutaneous · 7 daysAs given in this study (human).
Measurements
Baseline IGFBP-2 as share of control value
153%
Before IGF-I, adults with GHRD
IGFBP-2 increase
45%
During IGF-I therapy, adults with GHRD
P value for IGFBP-2 increase
< 0.01
During IGF-I therapy versus baseline, adults with GHRD
Source sentences
Summary
Although IGF-binding protein-3 (IGFBP-3) levels were not significantly influenced, baseline IGFBP-2 levels (153% of the control) increased 45% (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
Report a problemFND-0768691617

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

17HumanEndogenous levelObservational studyOther
Adults with GHRD had pretreatment IGF-I levels at 19% of the Ecuadorian control value.
In plain wordsAdults with GHRD had lower natural IGF-I levels than Ecuadorian controls.
Peptide
IGF-1 (mecasermin)
Outcome
DecreasePretreatment IGF-I versus controls
Study
n = 6
Comparator
Ecuadorian controls
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Pretreatment IGF-I
36 micrograms/L
adults with GHRD, before IGF-I
Control IGF-I
190 micrograms/L
Ecuadorian control value
Pretreatment IGF-I as share of control
19%
adults with GHRD vs Ecuadorian control
Source sentences
Summary
The mean pretreatment IGF-I level (36 +/- 2 micrograms/L) was 19% of the Ecuadorian control value (190 +/- 15 micrograms/L)
1 context sentence(design, population, supporting numbers)
Summary · context
We evaluated the pharmacokinetics and metabolic/hormonal effects of recombinant human IGF-I (40 micrograms/kg every 12 h) given sc for 7 days to six adults with GHRD.
This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0768691601

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.